Lilly Diabetes Extends National Sponsorship of the American Diabetes Association's Signature Tour de Cure® Cycling Event for a

     Lilly Diabetes Extends National Sponsorship of the American Diabetes
    Association's Signature Tour de Cure® Cycling Event for a Second Year

New sponsorship of "Red Riders®"--cyclists with diabetes--added in 5 cities

PR Newswire

INDIANAPOLIS, Nov. 19, 2013

INDIANAPOLIS, Nov. 19, 2013 /PRNewswire/ --

News Highlights:

  oFor a 2^nd year, #Lilly #Diabetes supports the American Diabetes
    Association's Tour de Cure cycling event to help #StopDiabetes
  oNew in 2014, #Lilly #Diabetes to support #RedRider cyclists with #diabetes
    in 5 cities
  oLilly Tour de Cure cycling teams increased #fundraising by 211% in 2013;
    954 #Lilly team riders helped raise $222,139 nationally

Lilly Diabetes today announced it will continue its national sponsorship of
the American Diabetes Association's (Association) Tour de Cure^® annual
cycling event for a second year in a row.

In 2013, more than 65,000 cyclists in 89 events in 44 states raised more than
$26 million to support the mission of the Association: to prevent and cure
diabetes and to improve the lives of all people affected by diabetes.

As a company, Lilly employees, family and friends joined together nationwide
to form 89 teams with 954 team riders, helping to raise $222,139 for people
with diabetes—a 211% increase in dollars raised compared to 2012.

"Participating in this event was a moving experience for me, and I know how
important it is to our employees to connect with and support people with
diabetes in their own communities," said Kevin Cammack, senior director of
marketing, U.S., Lilly Diabetes and chair of Lilly Diabetes' 2014 corporate
campaign. "We are proud to continue our support knowing that through this
collaboration and with a common goal, we are helping the Association improve
the lives of people with diabetes. We can't wait to get out there and ride for
people with diabetes once again."

For cycling events, the Tour de Cure is unique not only because it includes
riders at all levels of ability, but it also celebrates riders with diabetes,
known as Red Riders^®. The purpose of the Red Rider program is to support
anyone who lives with diabetes and highlight the courage it takes to live
every day with this challenging disease. Lilly shares the Association's belief
that these riders should be celebrated and will sponsor Red Riders for the
first time in Dallas, Denver, Indianapolis, Minneapolis and Princeton, N.J.

"The American Diabetes Association is thrilled to have Lilly Diabetes extend
their national sponsorship of the Association's signature Tour de Cure cycling
event for a second year," said Larry Hausner, MBA, chief executive officer,
American Diabetes Association. "Tour de Cure not only raises funds to help
Stop Diabetes^®, but it also celebrates our Red Riders and provides the
opportunity for people to come together and be physically active, which can
help people living with diabetes better manage their condition."

Diabetes is a chronic disease. The American Diabetes Association reports that
it affects nearly 26 million children and adults in the United States—8.3
percent of the U.S. population. It is estimated that an additional 79 million
have prediabetes, putting them at risk for developing type 2 diabetes.
Diabetes can lead to blindness, heart disease, stroke, kidney failure and
amputations. Some common symptoms/signs of diabetes are extreme thirst,
frequent urination, blurry vision, and tingling in the feet.

For more on Lilly Diabetes programs and resources, visit To get involved with the Tour de Cure or to register to
ride, visit Rides begin January 26, 2014.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and
growing product portfolio and a continued commitment to providing real
solutions—from medicines to support programs and more—to make lives better.
For more information, visit

About Eli Lilly and Company (NYSE: LLY)
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers—through medicines and information—for some of the world's most urgent
medical needs. Information about Lilly is available at

LD87221 11/2013 ©Lilly USA, LLC 2013. All rights reserved.


Julie Williams, Communications Manager Emily Kiggins
Lilly Diabetes                         MSLGROUP
317-627-4056 (mobile/text)             202-261-2898 (office)        

(Logo: )
(Logo: )

SOURCE Eli Lilly and Company

Press spacebar to pause and continue. Press esc to stop.